Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
Rhea-AI Summary
Rani Therapeutics, a Nasdaq-listed clinical-stage biotherapeutics company (RANI), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company, which focuses on oral delivery of biologics and drugs, will be represented by CEO Talat Imran and CFO Svai Sanford in a fireside chat.
The event is scheduled for Thursday, October 17, 2024, from 11:30 am to 12:00 pm E.T. in Track 2. Interested parties can access the live webcast of the conference through a provided registration link. This participation highlights Rani Therapeutics' engagement with the investment community and its commitment to sharing insights about its innovative approach to drug delivery.
Positive
- None.
Negative
- None.
News Market Reaction – RANI
On the day this news was published, RANI gained 7.31%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2.
Interested parties can register and access the live webcast for the conference here.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact: